Citius Oncology, Stock Number Of Shares Shorted
| CTOR Stock | 1.34 0.03 2.19% |
Fundamental analysis of Citius Oncology, allows traders to better anticipate movements in Citius Oncology,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Citius Oncology, Company Number Of Shares Shorted Analysis
Citius Oncology,'s Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Citius Oncology, Number Of Shares Shorted | 251.36 K |
Most of Citius Oncology,'s fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Citius Oncology, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Citius Oncology, has 251.36 K of outstending shares currently sold short by investors. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The number of shares shorted for all United States stocks is notably lower than that of the firm.
Citius Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Oncology,'s direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Oncology, could also be used in its relative valuation, which is a method of valuing Citius Oncology, by comparing valuation metrics of similar companies.Citius Oncology, is currently under evaluation in number of shares shorted category among its peers.
Citius Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 118.21 M | ||||
| Shares Outstanding | 83.51 M | ||||
| Shares Owned By Insiders | 88.66 % | ||||
| Shares Owned By Institutions | 0.92 % | ||||
| Number Of Shares Shorted | 251.36 K | ||||
| Price To Book | 3.53 X | ||||
| EBITDA | (20.57 M) | ||||
| Net Income | (21.15 M) | ||||
| Total Debt | 3.8 M | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | 126.35 K | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 6.0 | ||||
| Beta | 2.91 | ||||
| Market Capitalization | 111.91 M | ||||
| Total Asset | 84.37 M | ||||
| Retained Earnings | (39.28 M) | ||||
| Working Capital | (21.73 M) | ||||
| Net Asset | 84.37 M |
About Citius Oncology, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Citius Oncology,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Oncology, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Oncology, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving against Citius Stock
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.